Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacological Induction of Fetal Hemoglobin in β-Thalassemia and Sickle Cell Disease: An Updated Perspective

16 Jun 2022

Abstract excerpt

A significant amount of attention has recently been devoted to the mechanisms involved in hemoglobin (Hb) switching, as it has previously been established that the induction of fetal hemoglobin (HbF) production in significant amounts can reduce the severity of the clinical course in diseases such as β-thalassemia and sickle cell disease (SCD). While the induction of HbF using lentiviral and genome-editing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hemoglobinopathies and Related Disorders
Share to Iron Metabolism and Disorders
Share to Prenatal Screening and Diagnostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35745672
DOI: 10.3390/ph15060753

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacological Induction of Fetal Hemoglobin in β-Thalassemia and Sickle Cell Disease: An Updated PerspectivePMID 35745672Read ↗

Combined approaches for increasing fetal hemoglobin (HbF) and de novo production of adult hemoglobin (HbA) in erythroid cells from β-thalassemia patients: treatment with HbF inducers and CRISPR-Cas9 based genome editingSemantic proximity Read ↗

CRISPR-Cas9 to induce fetal hemoglobin for the treatment of sickle cell diseaseSemantic proximity Read ↗

Targeted Therapeutic Strategies for Fetal Hemoglobin InductionSemantic proximity Read ↗

Fetal haemoglobin induction in sickle cell diseaseSemantic proximity Read ↗

Targeting fetal hemoglobin expression to treat β hemoglobinopathiesSemantic proximity Read ↗

Pharmacological and molecular approaches for the treatment of β-hemoglobin disorders.Semantic proximity Read ↗

Genome Editing for β-Hemoglobinopathies: Advances and ChallengesSemantic proximity Read ↗

Fetal hemoglobin regulation in β-thalassemia: heterogeneity, modifiers and therapeutic approachesSemantic proximity Read ↗

A Small Key for a Heavy Door: Genetic Therapies for the Treatment of HemoglobinopathiesSemantic proximity Read ↗

A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition.Semantic proximity Read ↗

Clinical genome editing to treat sickle cell disease—A brief updateSemantic proximity Read ↗

Understanding mechanisms of gamma-globin gene regulation to develop strategies for pharmacological fetal hemoglobin induction.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.